Ineligibility required for 'anti-trials': inclusion in studies regardless of fitness

Vosaroxin for relapsed AML: Updates from VALOR

Impact of next-generation sequencing on treatment choice for MDS

Obinutuzumab extends PFS for follicular lymphoma in GALLIUM trial

Venetoclax plus cytarabine in elderly AML patients

Intravenous or subcutaenous rituximab for FL in the SABRINA study

Ibrutinib in CLL: RESONATE and resistance

Durable remissions with the VcR-CVAD regimen for MCL regardless of age

Tailoring therapy for leukaemia patients

Updates from the EURO-SKI trial of tyrosine kinase cessation

Incidence and risk factors for central venous catheter related thrombosis in children

CML patients with stable response may safely decrease dose of TKI